ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

PRME Prime Medicine Inc

5.40
-0.19 (-3.40%)
06 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Prime Medicine Inc PRME NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.19 -3.40% 5.40 16:15:45
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
5.65 5.39 5.77 5.40 5.59
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
01/5/202407:00GLOBEPrime Medicine to Participate in the 27th Annual Milken..
29/4/202406:00GLOBEPrime Medicine Announces FDA Clearance of Investigational..
23/4/202407:00GLOBEPrime Medicine to Present Preclinical Data Demonstrating..
01/3/202407:09EDGAR2Form S-8 - Securities to be offered to employees in employee..
01/3/202407:04EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
01/3/202407:01EDGAR2Form 8-K - Current report
01/3/202407:00GLOBEPrime Medicine Reports Full Year 2023 Financial Results and..
28/2/202407:00GLOBEPrime Medicine to Participate in Upcoming Investor..
23/2/202416:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202416:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202420:31EDGAR2Form SC 13D - General statement of acquisition of beneficial..
20/2/202416:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202415:01GLOBEPrime Medicine Announces Closing of Upsized Public Offering..
16/2/202405:23EDGAR2Form 8-K - Current report
16/2/202405:17EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/2/202422:50GLOBEPrime Medicine Announces Pricing of Upsized Public Offering
14/2/202420:57EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
14/2/202416:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/2/202415:12EDGAR2Form 8-K - Current report
14/2/202415:05GLOBEPrime Medicine Announces Proposed Public Offering of Common..
25/1/202407:00GLOBEPrime Medicine Receives Up to $15 Million from Cystic..
08/1/202407:01EDGAR2Form 8-K - Current report
05/1/202416:03EDGAR2Form 8-K - Current report
05/1/202407:15EDGAR2Form 8-K - Current report
05/1/202407:00GLOBEPrime Medicine Appoints Allan Reine, M.D., as Chief..
02/1/202407:00GLOBEPrime Medicine to Present at 42nd Annual J.P. Morgan..
13/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
08/11/202307:00GLOBEPrime Medicine to Present at Upcoming Investor Conferences
03/11/202316:23EDGAR2Form S-3 - Registration statement under Securities Act of..
03/11/202316:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202315:06EDGAR2Form 8-K - Current report
03/11/202315:01GLOBEPrime Medicine Reports Third Quarter 2023 Financial Results..
27/10/202305:00GLOBEPrime Medicine Presents First-ever Prime Editing Data in..
24/10/202306:30GLOBEPrime Medicine Presents First In Vivo Proof-of-Concept Prime..
17/10/202307:00GLOBEPrime Medicine to Highlight Positive Preclinical..
19/9/202307:00GLOBEPrime Medicine to Present at Upcoming Investor Conferences
31/8/202307:00GLOBEPrime Medicine to Present at Upcoming Investor Conferences
07/8/202315:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202315:04EDGAR2Form 8-K - Current report
07/8/202315:01GLOBEPrime Medicine Reports Second Quarter 2023 Financial Results..
22/6/202307:00GLOBEPrime Medicine and Cimeio Therapeutics Announce Research..
31/5/202307:00GLOBEPrime Medicine to Present at Investor Conferences in June
17/5/202315:05GLOBEPrime Medicine to Present at Virtual Investor Conferences in..
17/5/202305:00GLOBEPrime Medicine to Present New Preclinical Data Highlighting..
11/5/202307:00GLOBEPrime Medicine Reports First Quarter 2023 Financial Results..

Su Consulta Reciente

Delayed Upgrade Clock